ArticleNeurobiology of disease2018
Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease.
Open access · greenAbstract read
In one paragraph
Article in Neurobiology of disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Dopamine and Dopamine Receptors in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.Frontiers in aging neuroscience · 2019Pooled it
- A lifespan staging model of basal forebrain cholinergic vulnerability.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Pretangle tau pathology accrual in the default mode network during the progression of Alzheimer's disease.Molecular neurodegeneration advances · 2026Article
- The Intricate Relationship of Trk Receptors in Brain Diseases and Disorders.Molecular neurobiology · 2025Review
- Neuronal gene profiling of tau oligomer-bearing cholinergic nucleus basalis neurons during the onset of Alzheimer's disease.Acta neuropathologica communications · 2025Article
- Alzheimer's Disease and Frontotemporal Dementia: A Review of Pathophysiology and Therapeutic Approaches.Journal of neuroscience research · 2025Review
- Adolescent Alcohol and the Spectrum of Cognitive Dysfunction in Aging.Advances in experimental medicine and biology · 2025Review
- Advances in Brain Stimulation, Nanomedicine and the Use of Magnetoelectric Nanoparticles: Dopaminergic Alterations and Their Role in Neurodegeneration and Drug Addiction.Molecules (Basel, Switzerland) · 2024Review
- Oligomeric, phosphorylated, and truncated tau and spliceosome pathology within the entorhinal-hippocampal connectome across stages of Alzheimer's disease.The Journal of comparative neurology · 2023Article
- Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels.Molecular neurodegeneration · 2022Article
- Role of Cholinergic Signaling in Alzheimer's Disease.Molecules (Basel, Switzerland) · 2022Review
- Role of cyclin-dependent kinase 5 in early brain injury following experimental subarachnoid hemorrhage.Experimental and therapeutic medicine · 2022Article
- Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective.Free neuropathology · 2022Article
- In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer's disease phases.Alzheimer's research & therapy · 2021Article
- Synapsin-caveolin-1 gene therapy preserves neuronal and synaptic morphology and prevents neurodegeneration in a mouse model of AD.Molecular therapy. Methods & clinical development · 2021Article
- Expression profiling of precuneus layer III cathepsin D-immunopositive pyramidal neurons in mild cognitive impairment and Alzheimer's disease: Evidence for neuronal signaling vulnerability.The Journal of comparative neurology · 2020Article
- The relationship between olfaction and cognitive function in the elderly.The journal of physiological sciences : JPS · 2020Article
- AVP(4-8) Improves Cognitive Behaviors and Hippocampal Synaptic Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease.Neuroscience bulletin · 2020Article
- Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings.Journal of Alzheimer's disease reports · 2019Review
- Peri-Infarct Upregulation of the Oxytocin Receptor in Vascular Dementia.Journal of neuropathology and experimental neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Chelsea T TiernanDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Stephen D GinsbergCenter for Dementia Research, Nathan Kline Institute, Orangeburg, NY, USA; Department of Psychiatry, NYU Langone School of Medicine, New York, NY, USA; Department of Physiology & Neuroscience, NYU Langone School of Medicine, New York, NY, USA; NYU Neuroscience Institute, NYU Langone School of Medicine, New York, NY, USA.
Bin HeDepartment of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA.
Sarah M WardDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA.
Angela L Guillozet-BongaartsAllen Institute for Brain Science, Seattle, WA, USA.
Nicholas M KanaanDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA; Hauenstein Neurosciences Center, Mercy Health Saint Mary's Hospital, Grand Rapids, MI, USA.
Elliott J MufsonDepartment of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA.
Scott E CountsDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA; Hauenstein Neurosciences Center, Mercy Health Saint Mary's Hospital, Grand Rapids, MI, USA; Department of Family Medicine, Michigan State University, Grand Rapids, MI, USA; Michigan Alzheimer's Disease Core Center, Ann Arbor, MI, USA. Electronic address: scott.counts@hc.msu.edu.
Barrow Neurological Institute · USMichigan State University · USTrinity Health Grand Rapids · USAllen Institute for Brain Science · USNathan Kline Institute for Psychiatric Research · US
Funding
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI LEURGANS, SUE E. · 1991 to 2020
$49.1MUncovering Alzheimer's disease risk mechanisms through neuron-specific analysis of autophagy and endosomal-lysosomal functionP01AG017617 · NIA · NATHAN S. KLINE INSTITUTE FOR PSYCH RES · PI NIXON, RALPH A. · 2000 to 2021
$40.0MTAU, AB, SYNUCLEIN AND NITRATIVE/OXIDATIVE DAMAGE IN MCIP01AG014449 · NIA · UNIVERSITY OF PITTSBURGH · PI COUNTS, SCOTT E · 1997 to 2024
$39.7MResearch Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5MMichigan Alzheimer's Disease Core CenterP30AG053760 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALBIN, ROGER L · 2016 to 2020
$10.1MTau Conformation in Tauopathies and Neuronal FunctionR01NS082730 · NINDS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BRADY, SCOTT THOMAS, KANAAN, NICHOLAS M · 2014 to 2023
$7.0MCellular and Molecular Medial Temporal Lobe Pathology in Elderly PreMCI subjectsR01AG043375 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI GINSBERG, STEPHEN D, MUFSON, ELLIOTT JAY · 2013 to 2017
$3.6MTau-induced axonal degeneration in Alzheimer's disease and tauopathiesR01AG044372 · NIA · MICHIGAN STATE UNIVERSITY · PI KANAAN, NICHOLAS M · 2014 to 2018
$1.9MMolecular profiling of familial and sporadic Alzheimer's diseaseR21AG053581 · NIA · MICHIGAN STATE UNIVERSITY · PI COUNTS, SCOTT E · 2016 to 2017
$426kNIA NIH HHS P01 AG014449NIA NIH HHS P01 AG017617NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG053760NIA NIH HHS R01 AG043375NIA NIH HHS R01 AG044372NIA NIH HHS R21 AG053581NINDS NIH HHS R01 NS082730
Abstract
Cholinergic basal forebrain neurons of the nucleus basalis of Meynert (nbM) regulate attentional and memory function and are exquisitely prone to tau pathology and neurofibrillary tangle (NFT) formation during the progression of Alzheimer's disease (AD). nbM neurons require the neurotrophin nerve growth factor (NGF), its cognate receptor TrkA, and the pan-neurotrophin receptor p75
Indexed as
Disease ProgressionNerve Growth FactorsAgedAged, 80 and overAlzheimer DiseaseBasal Nucleus of MeynertCholinergic NeuronsFemaleHumansMaleNerve Growth FactorNerve Tissue ProteinsNeurofibrillary TanglesReceptor, Nerve Growth FactorReceptors, Nerve Growth FactorReceptors, NeurotransmitterNerve Growth FactorNerve Growth FactorsNerve Tissue ProteinsNGF protein, humanNGFR protein, humanReceptor, Nerve Growth FactorReceptors, Nerve Growth FactorReceptors, NeurotransmitterAcetylcholine receptorAdrenoceptorCholinergic basal forebrainDopamine receptorGlutamate receptorMild cognitive impairmentNeurotransmissionNeurotrophinNucleus basalis of MeynertTrk receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.